| HOME >> BIOLOGY >> TECHNOLOGY |
Basic and diluted net
loss per share: ($0.34) ($0.41) ($0.70) ($0.61)
Shares used in
calculation of basic
and diluted net loss
per share: 56,359 56,170 56,316 56,148
(1) Stock-based compensation expenses included in operating expenses
amounted to approximately:
Research and development $467 $723 $1,127 $1,891
Selling, general and
administrative 876 1,296 1,755 2,533
IDENIX PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS)
(UNAUDITED)
June 30, December 31,
2008 2007
ASSETS
Cash and cash equivalents $ 54,062 $ 48,260
Marketable securities 16,270 39,862
Receivables from related party 1,727 11,196
Other current assets 3,221 4,401
Total current assets 75,280 103,719
Intangible asset, net 12,968 13,548
Property and equipment, net 14,873 15,460
Marketable securities, non-current 10,308 23,882
Other assets 3,852 3,931
Total assets $ 117,281 $ 160,540
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts payable and accrued expenses $ 15,953 $ 21,809
Deferred revenue, related party 7,766 8,372
Other current liabilities 64
'/>"/>
| SOURCE Idenix Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |